Pfizer's Monthly Obesity Shot Heats Up GLP-1 Race, Posing New Challenge to Novo Nordisk
Pfizer's promising mid-stage trial results for its monthly injectable obesity drug, Metsera, signal a credible new competitor for market leaders Novo Nordisk and Eli Lilly, prompting analysts to flag intensifying rivalry in the lucrative weight-loss therapeutics sector.